

1
2
3 **Title: Pharmaceutical Compounding**
4
5 **Introduced by: Domenic R. Federico MD, for the Kent County Delegation**
6
7 **Original Author: David E. Hammond, MD**
8
9 **Referred to: Reference Committee D**
10
11 **House Action: Approved as Amended**
12

13
14 **Whereas, Michigan Senate Bill 704 introduced by Senator Joe Hune**
15 **establishes new requirements for pharmacies involved in sterile compounding,**
16 **and**
17

18 **Whereas, Senate Bill 704 is the result of the Compounding Clarity Act of**
19 **2013 as proposed by Senator Thomas Harkin (D-Iowa), and**
20

21 **Whereas, this act establishes new compounding laws at the federal level,**
22 **and**
23

24 **Whereas, the legislation at both federal and state levels was introduced**
25 **to address the recent outbreak of fungal meningitis linked to a compounding**
26 **scandal at the New England Compounding Center that sickened 751 patients in**
27 **19 states resulting in 64 deaths. 264 of those cases and 19 deaths occurred in**
28 **Michigan, and**
29

30 **Whereas, adding unnecessary requirements by the Michigan Department**
31 **of Licensing and Regulatory Affairs (LARA) will impede access to patient care**
32 **and interfere with the patient-physician relationship, and**
33

34 **Whereas, consultation with the pharmacists and physicians who**
35 **compound and use these products would increase the chance that the resultant**
36 **products would be safe and effective and meet manufacturing standards**
37 **without restricting access to the important products, and**
38

39 **Whereas, physicians rely heavily on compounded pharmaceutical**
40 **products especially topical products obtained via traditional compounding**
41 **pharmacies to treat many skin and systemic diseases, and**
42

43 **Whereas, the use of these compounded medications is an integral part of**
44 **most medical practices. Prescribing and/or directly administering compound**
45 **medications allows physicians to tailor treatment to the unique needs of their**
46 **patients while at the same time safely delivering treatment resulting in better**
47 **therapeutic outcomes, and**

48 **Whereas, physicians must maintain full access to topical compounded**
49 **products including their in-office use without overly burdensome regulatory**
50 **restrictions at both the federal and state level, and**

51
52 **Whereas, such restrictions could lead to unintended consequences**
53 **including limited or delayed access to needed treatments, and**

54
55 **Whereas, such delays could potentially result in increased patient**
56 **morbidity and unnecessary increases in health care expenses, thus, patients**
57 **should have access to treatment with a compounded product in a timely**
58 **manner; therefore be it**

59
60 **RESOLVED: That MSMS works with LARA and other interested parties to**
61 **ensure quality and safety of compounded prescriptions while not limiting**
62 **physician access to needed compounds for patients; and be it further**

63
64 **RESOLVED: That MSMS support a reasonable and accurate track and**
65 **trace system of compounded products to provide an added safeguard to enable**
66 **appropriate investigation of any identified injury or danger to patients.**

67
68
69 **WAYS AND MEANS COMMITTEE FISCAL NOTE: NONE**
